Regeneron Pharmaceuticals Q4 Adjusted EPS $11.86 Beats $10.77 Estimate, Sales $3.43B Beat $3.29B Estimate
Portfolio Pulse from Benzinga Newsdesk
Regeneron Pharmaceuticals reported Q4 adjusted EPS of $11.86, surpassing the $10.77 estimate, and sales of $3.43B, exceeding the $3.29B estimate. This represents a 5.57% decrease in EPS and a 0.59% increase in sales from the same period last year.
February 02, 2024 | 11:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Regeneron Pharmaceuticals exceeded Q4 EPS and sales estimates, with a slight year-over-year decrease in EPS but an increase in sales.
Beating both EPS and sales estimates typically has a positive impact on a company's stock price in the short term. Despite the year-over-year decrease in EPS, the growth in sales and the significant beat on estimates are likely to be viewed positively by investors. The importance is rated high due to the direct impact on investor perception of the company's financial health and performance.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100